Drugs / Cusatuzumab
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT04241549 | Mar 2020 → Jul 2021 | acute myeloid leukemia | OncoVerity, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04150887 | Dec 2019 → May 2027 expected | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02759250 | Feb 2015 → Apr 2018 | cancer | argenx | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT03030612 | Dec 2016 → Aug 2022 | acute myeloid leukemia, myelodysplastic syndrome | OncoVerity, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01813539 | Feb 2013 → Jul 2020 | neoplasm | OncoVerity, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06384261 | Jul 2024 → Jan 2027 expected | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04264806 | May 2021 → Apr 2022 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04023526 | Jul 2019 → Aug 2023 overdue | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cusatuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06384261 ↗ |
| Known as | ARGX-110 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01813539 ↗ |
| Action | Inhibit | “ARGX-110, a defucosylated IgG1 monoclonal antibody (mAb) that selectively targets and neutralizes CD70, the ligand of CD27.” PMID 24492296 ↗ Dec 2013 |
| Modality | Monoclonal antibody | “ARGX-110, a defucosylated IgG1 monoclonal antibody (mAb) that selectively targets and neutralizes CD70, the ligand of CD27.” PMID 24492296 ↗ Dec 2013 |
| Route | Intravenous | “ARGX-110 will be administered as an IV infusion.” NCT01813539 ↗ |
| Target | CD70 | “ARGX-110, a defucosylated IgG1 monoclonal antibody (mAb) that selectively targets and neutralizes CD70, the ligand of CD27.” PMID 24492296 ↗ Dec 2013 |